Daniel Auclair, Myeloproliferative Syndromes
Daniel Auclair/X

Daniel Auclair: Key ASH 2025 Updates on Emerging LBCL Therapies

Daniel Auclair, President of Hematocure, shared a post on X:

“1. ASH25 LBCL

Dual CD19/CD20: Kite-363 Dr. Saurabh Dahiya, Dr. Sairah Ahmed
Read the full article.

Ronde-cel Dr. Sarah Larson, Dr. Akil Merchant
Read the full article.

Zamto-cel Dr. Peter Borchmann, Dr. Nirav Shah
Read the full article.

2. ASH25 new agents for LBCL

CelMod Golcadomide: Dr. Grzegorz Nowakowski, Dr. Jason Westin
Read the full article.

Dr. Marc Hoffmann, Dr. Jason Westin, Dr. J M Michot
Read the full article.

Bcl-6 degrader BMS-986458: Dr. Franck Morschhauser, Dr. J M Michot
Read the full article.”

More posts featuring Daniel Auclair.